Posted by Michael Wonder on 20 Jun 2019
Institute for Clinical and Economic Review issues final report and policy recommendations on siponimod for secondary progressive multiple sclerosis
20 June 2019 - Independent appraisal committee votes that evidence is adequate to demonstrate siponimod offers superior effectiveness for patients with active SPMS, but not inactive SPMS, compared to best supportive care.
The ICER today released a final evidence report and Report-at-a-Glance assessing the comparative clinical effectiveness and value of siponimod (Mayzent, Novartis) for the treatment of secondary progressive multiple sclerosis (SPMS).
Siponimod was recently approved by the FDA for the treatment of relapsing forms of multiple sclerosis, including active SPMS. However, ICER’s assessment focuses on the clinical and cost-effectiveness of siponimod just for patients with SPMS (both active and non-active), which was the population studied in the phase III trial.
